High-dose therapy with @entity8 ( @entity8 ) has been widely used in the past decade for treating @entity1893 in situations in which conventional therapy was not likely to cure @entity1 . In @entity1 achieving complete remission (CR), @entity8 has been proposed for consolidation in a group of @entity706 @entity1 sharing adverse prognostic factors with a high risk of relapse. Results from pilot studies were encouraging. Analysis of the large randomized LNH87 trial showed an increased survival and disease-free survival advantage for @entity8 performed after CR when compared to conventional chemotherapy if @entity1 with two or more adverse factors were included. For @entity1 who do not achieve CR after conventional treatment, but who are still sensitive to chemotherapy, @entity8 may improve results. Pilot studies as well as randomized studies offer support for this approach. Intensive treatment with @entity8 has been reported in thousands of relapsing @entity706 @entity1 . For those remaining sensitive to salvage chemotherapy at 5 years, a 40% probability of disease-free survival has been uniformly noted. Moreover, these results were confirmed by the randomized PARMA study testing @entity8 vs conventional chemotherapy, @entity8 is accepted by most centers as the treatment of choice for relapsing @entity706 . For @entity981 and @entity2109 , the role of @entity8 in first CR is not well defined, although results from pilot studies and the analysis of registry data support the use of @entity8 in @entity981 with adverse prognostic factors. In conclusion, data supporting the use of @entity8 in @entity706 in different settings has been provided by numerous nonrandomized trials. Completed randomized studies clearly demonstrate a benefit for @entity8 in most relapsing @entity1 as well as a subset of @entity1 with poor prognosis. The socioeconomic implications of such results must be evaluated, especially since the development of peripheral hematopoietic stem cells will reduce both @entity137 and cost.

Autologous stem cell transplantation in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['autologous stem cell transplantation', 'ASCT'] @entity981 :: ('MESH:D054198', 'Disease') :: ['lymphoblastic lymphoma'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma'] @entity2109 :: ('MESH:D002051', 'Disease') :: ["Burkitt's lymphoma"] @entity1893 :: ('MESH:D008228', 'Disease') :: ["aggressive non-Hodgkin's lymphoma"]
@entity1893 :: (MESH:D008228,Disease) :: ['aggressive non-Hodgkin's lymphoma']
